TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 389839

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg vs Propranolol 80 mg
Number of subjects: 60
Study: 30142886

Group type: EXPERIMENTAL
Intervention: ADF + DER
Number of subjects: 162

Group type: COMPARATOR
Intervention: DER
Number of subjects: 162
Study: 27131077

Group type: EXPERIMENTAL
Intervention: Daily boost of 0.5 Gy to the tumor bed
Number of subjects: 400

Group type: COMPARATOR
Intervention: Weekly boost of 2 Gy to the tumor bed
Number of subjects: 400
Study: 24739135

Group type: EXPERIMENTAL
Intervention: Carotid revascularisation in patients with an ipsilateral foetal-type posterior cerebral artery
Number of subjects: 98

Group type: COMPARATOR
Intervention: Carotid revascularisation in patients with a normal posterior cerebral artery
Number of subjects: 98
Study: 22492586

Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg QD
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg QD
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg QD
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg QD
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg BID
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg QD
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 451
Study: 19582490

Group type: EXPERIMENTAL
Intervention: Preference valuation set for EQ-5D health states derived from the general Flemish public
Number of subjects: 548

Group type: COMPARATOR
Intervention: Comparison with health state valuations from other countries
Number of subjects: 548
Study: 17974534

Group type: EXPERIMENTAL
Intervention: Exacta small screw titanium implants (Exacta MS series conical profile, diameter 3.3 mm, length 7.0 mm)
Number of subjects: 16
Study: 16330290

Group type: EXPERIMENTAL
Intervention: Glimepiride (titrated from 2 to 4 to 8 mg/d over 6 weeks, followed by 20 weeks of maintenance therapy)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: COMPARATOR
Intervention: Glimepiride and Placebo
Number of subjects: 170
Study: 11949926

Group type: EXPERIMENTAL
Intervention: Physician mammography reminders
Number of subjects: 0
Study: 9628124

Group type: EXPERIMENTAL
Intervention: 5 mg L-846
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 mg L-846
Number of subjects: 11
Study: 7839093

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (40 mg three times daily, loading dose 80 mg) and amoxicillin (2 g three times daily for 3 days, then 20 mg omeprazole twice daily and 1 g amoxicillin twice daily orally for 11 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omeprazole (40 mg three times daily, loading dose 80 mg) intravenously for 3 days and 20 mg omeprazole twice daily and 1 g amoxicillin twice daily orally for 11 days
Number of subjects: 20
Study: 3279756

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at 6 PM
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ranitidine 300 mg at 10 PM
Number of subjects: 141
Study: 31477542

Group type: EXPERIMENTAL
Intervention: Intensive TBS (3 intermittent TBS treatments per day for 3 days in week 1, 3 treatments a day for 2 days in week 2, and 3 treatments in 1 day in week 3 and in week 4)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard rTMS (5 daily sessions per week for 4 weeks)
Number of subjects: 74
Study: 27455886

Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (MTX) 7.5 mg twice or thrice weekly
Number of subjects: 135

Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX) 15 mg or 22.5 mg in a single dose weekly
Number of subjects: 135

Group type: COMPARATOR
Intervention: Parenteral Methotrexate (MTX) 15 mg or 22.5 mg in a single dose weekly
Number of subjects: 135
Study: 26354605

Group type: EXPERIMENTAL
Intervention: Sake yeast supplementation (500 mg of sake yeast powder)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 68
Study: 26564511

Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFUS) in slightly-painful group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFUS) in extremely-painful group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFUS) in painless group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional clinical treatment evaluations
Number of subjects: 24
Study: 24297959

Group type: EXPERIMENTAL
Intervention: Superelastic nickel-titanium archwires
Number of subjects: 85

Group type: COMPARATOR
Intervention: Multistranded stainless steel archwires
Number of subjects: 85
Study: 21593045

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 18398348

Group type: EXPERIMENTAL
Intervention: Ramipril, 10 mg once daily for 24 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17067330

Group type: EXPERIMENTAL
Intervention: Stimulating catheter
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional catheter
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Stimulating catheter with 100-ml bags of ropivacaine 2 mg/ml
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional catheter with 100-ml bags of ropivacaine 2 mg/ml
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Stimulating catheter with 200-ml bags of ropivacaine 2 mg/ml
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional catheter with 200-ml bags of ropivacaine 2 mg/ml
Number of subjects: 76
Study: 12807937

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2
Number of subjects: 271

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m2
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 with filgrastim 5 microg/kg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 with filgrastim 10 microg/kg
Number of subjects: 271

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m2 without filgrastim
Number of subjects: 271
Study: 11140555

Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral with porcine derived collagen membrane
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 22
Study: 9192506

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulated (FES) upright cycling for 12 months, 30 min per day, 3 days per week
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reduced training (one weekly session for 6 months)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FES cycle training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (age-matched individuals)
Number of subjects: 10
Study: 7999161

Group type: EXPERIMENTAL
Intervention: Cooling pads at 40 degrees F
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cooling pads at 45 degrees F
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cooling pads at 55 degrees F
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cooling pads at 70 degrees F
Number of subjects: 131

Group type: COMPARATOR
Intervention: No cooling pads
Number of subjects: 131
Study: 3069479

Group type: EXPERIMENTAL
Intervention: 15 mg chlorambucil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 40 mg chlorambucil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 60 mg chlorambucil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 70 mg chlorambucil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Phenyl acetic acid mustard (metabolite)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dose-corrected AUC for chlorambucil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dose-corrected AUC for metabolite
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chlorambucil and metabolite
Number of subjects: 5
Study: 31509072

Group type: EXPERIMENTAL
Intervention: Project Mothers and Schools (Project MAS)
Number of subjects: 84
Study: 31008545

Group type: EXPERIMENTAL
Intervention: 0.9 g MMT/kg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 0.6 g MMT/kg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 0.3 g MMT/kg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 1.2 g MMT/kg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: MMT supplementation
Number of subjects: 480
Study: 28783464

Group type: EXPERIMENTAL
Intervention: MLS laser therapy and exercises
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LLLT and exercises
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo laser therapy plus exercises (PL + EX)
Number of subjects: 75
Study: 25217123

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg i.v.)
Number of subjects: 40
Study: 22716148

Group type: EXPERIMENTAL
Intervention: THC 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: CBD 600 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20083523

Group type: EXPERIMENTAL
Intervention: Play Nicely educational program (intervention group, n = 130)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Play Nicely educational program (intervention group, n = 59 Spanish-speaking caregivers)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Play Nicely educational program (intervention group)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Standard care (control group, n = 129)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 259
Study: 17438314

Group type: EXPERIMENTAL
Intervention: Sequential therapy (40 mg of pantoprazole, 1 g of amoxicillin, and placebo for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily for 10 days)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 300
Study: 15627534

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of naloxone (1.2 mg over 48 h) and morphine (6 mg over 48 h) in 0.1% bupivacaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Continuous epidural morphine (6 mg over 48 h) in 0.1% bupivacaine
Number of subjects: 58
Study: 12131417

Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar fusion with Cotrel‐Dubousset instrumentation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion without instrumentation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups (instrumented and noninstrumented)
Number of subjects: 130
Study: 10205983

Group type: EXPERIMENTAL
Intervention: Triclosan-containing toothpaste (CAOLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing dentifrices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triclosan-containing dentifrices
Number of subjects: 0
Study: 7955179

Group type: EXPERIMENTAL
Intervention: Baseline D-dimer concentration exceeding the 95th percentile of the control distribution
Number of subjects: 296
Study: 2636388

Group type: EXPERIMENTAL
Intervention: Variants of the English rise‐fall‐rise pattern
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPC resynthesis stimuli with varying F0 rise‐fall alignment
Number of subjects: 0
Study: 1099172

Group type: EXPERIMENTAL
Intervention: Apomorphine HCl (1 mg) administered subcutaneously three times a day for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Distilled water (placebo) administered subcutaneously three times a day for 14 days
Number of subjects: 40
Study: 31065841

Group type: EXPERIMENTAL
Intervention: High-frequency intensive balneotherapy (3 weeks)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Low-frequency balneotherapy followed by land-based exercise (3 weeks of each)
Number of subjects: 236
Study: 28952295

Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanate potassium
Number of subjects: 146

Group type: COMPARATOR
Intervention: Ceftezole sodium
Number of subjects: 146
Study: 25649019

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTEN status
Number of subjects: 0
Study: 22917440

Group type: EXPERIMENTAL
Intervention: Beyond + artificial saliva (AS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Beyond + distilled water (DW)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control + HS
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Opalescence Boost (O‐Boost) + HS
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Opalescence Boost (O‐Boost) + AS
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Opalescence Boost (O‐Boost) + DW
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Beyond + HS
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control + AS
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control + DW
Number of subjects: 108
Study: 21566113

Group type: EXPERIMENTAL
Intervention: Intravenous sodium thiosulfate (STS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral sodium thiosulfate (STS)
Number of subjects: 19
Study: 19232560

Group type: EXPERIMENTAL
Intervention: Femtosecond laser arcuate keratotomy (AK)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanized arcuate keratotomy (AK)
Number of subjects: 20
Study: 16549458

Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]-leucine oxidation measured after a primed, continuous oral administration of the tracer in the postabsorptive state
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-[1-(13C)]-leucine oxidation measured after a primed, continuous oral administration of the tracer in the fed state
Number of subjects: 21
Study: 14514224

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with enamel matrix derivative (EMD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coronally advanced flap with subepithelial connective tissue graft
Number of subjects: 20
Study: 10699322

Group type: EXPERIMENTAL
Intervention: 5-125 microg rPspA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-immune sera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human anti-rPspA
Number of subjects: 0
Study: 9327194

Group type: EXPERIMENTAL
Intervention: rifaximin 400 mg three times daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: neomycin 1 g three times daily
Number of subjects: 49
Study: 8268780

Group type: EXPERIMENTAL
Intervention: Behavioral-based interventions to help women overcome personal barriers
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Preventive orientation measured by smoking status
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Concerns about mammography
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Difficulty getting to the screening center
Number of subjects: 663
Study: 2870223

Group type: EXPERIMENTAL
Intervention: InterVir-A (IVA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 69
Study: 31898766

Group type: EXPERIMENTAL
Intervention: ASL alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All sequences including 4D CE MRA
Number of subjects: 24
Study: 30140071

Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at birth (umbilical cord sample)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at 48-72 hours
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at 4 months
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Reticulocyte hemoglobin content (Ret‐He) measured at 12 months
Number of subjects: 456
Study: 26424731

Group type: EXPERIMENTAL
Intervention: Supervised exercise for 16 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Counselling without dietary modification for 16 weeks
Number of subjects: 69
Study: 25799848

Group type: EXPERIMENTAL
Intervention: Smoking smelters
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Smokers smoking ≥20 cigarettes per day
Number of subjects: 166

Group type: COMPARATOR
Intervention: Non-smoking smelters
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (unexposed subjects)
Number of subjects: 166
Study: 22984150

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB) with ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical infiltration of ropivacaine
Number of subjects: 40
Study: 20863008

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 10 mg p.o.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 20 mg p.o.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 30 mg p.o.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 10 mg i.m.
Number of subjects: 12
Study: 19127824

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety-state
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety-trait
Number of subjects: 83
Study: 16003055

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 4 microg/kg/min for 6 hrs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 8 microg/kg/min for 6 hrs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study: 12091844

Group type: EXPERIMENTAL
Intervention: Early rhEPO (750 IU/kg/week for 9 weeks)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Late rhEPO (750 IU/kg/week for 6 weeks)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control (no rhEPO)
Number of subjects: 219
Study: 10483821

Group type: EXPERIMENTAL
Intervention: Ondansetron 24 mg q.d.
Number of subjects: 357

Group type: COMPARATOR
Intervention: Ondansetron 8 mg b.i.d.
Number of subjects: 357

Group type: COMPARATOR
Intervention: Ondansetron 32 mg q.d.
Number of subjects: 357
Study: 8694672

Group type: EXPERIMENTAL
Intervention: 60 mg of intramuscular ketorolac tromethamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 25 mg of intravenous chlorpromazine hydrochloride
Number of subjects: 30
Study: 1928881

Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen (5 mg hydrocodone with 500 mg acetaminophen)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Codeine/acetaminophen (30 mg codeine with 500 mg acetaminophen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Codeine/acetaminophen
Number of subjects: 50
Study: 7154835

Group type: EXPERIMENTAL
Intervention: Naloxone (NLX) 0.4 mg i.v.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 22
Study: 30724666

Group type: EXPERIMENTAL
Intervention: Registry-based randomized clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TASTE study
Number of subjects: 0
Study: 28333511

Group type: EXPERIMENTAL
Intervention: In-person brief alcohol intervention (BAI)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Computer-based brief alcohol intervention (BAI)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 961
Study: 26547700

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dry extract (120mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (60mg/day)+vitamin C (600mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: papaverine hydrochloride (100mg/day)+vitamin E (400mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 24886066

Group type: EXPERIMENTAL
Intervention: C-reactive protein testing (CRP) in the intervention group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no CRP testing)
Number of subjects: 179
Study: 21284552

Group type: EXPERIMENTAL
Intervention: Crestal implant placement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subcrestal implant placement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Crestal and Subcrestal implant placement
Number of subjects: 24
Study: 20228003

Group type: EXPERIMENTAL
Intervention: MgSO₄ 6.4% (2.5 mL) administered in 3 nebulisations at 30 minute intervals
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17872451

Group type: EXPERIMENTAL
Intervention: Nateglinide (270 mg/dL)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 78
Study: 15000508

Group type: EXPERIMENTAL
Intervention: Positive mood condition
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Neutral mood condition
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Drinking motives
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 302
Study: 11720177

Group type: EXPERIMENTAL
Intervention: Sugar (verum challenge)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (placebo challenge)
Number of subjects: 30
Study: 9164228

Group type: EXPERIMENTAL
Intervention: Oral dolasetron 200 mg and oral dexamethasone 20 mg (one-dose regimen)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral dolasetron 200 mg and oral dexamethasone 20 mg (two-dose regimen)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: One-dose regimen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Two-dose regimen
Number of subjects: 75
Study: 7957541

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Cholestyramine (16 g)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine (4 g)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine (8 g)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine (16 g)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fluvastatin and Cholestyramine (all doses)
Number of subjects: 151
Study: 3608372

Group type: EXPERIMENTAL
Intervention: Citrate administration (5 mmol of calcium chloride and 21 mmol of citrate in the form of sodium potassium citrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Citrate-free vehicle load
Number of subjects: 8
Study: 29125655

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 1000